7-bromo-2-methyl-3-formylindol | 691887-86-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 7-bromo-2-methyl-3-formylindol
• 英文别名: 7-bromo-2-methyl-1H-indole-3-carbaldehyde
• CAS: 691887-86-2
• 化学式: C₁₀H₈BrNO
• 分子量: 238.084
• InChiKey: VOVNJHWNSVPDCL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  32.9
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  7-bromo-2-methyl-3-formylindol 、 2-羟基丁二腈 在 哌啶 作用下， 以 乙醇 为溶剂， 生成 2-(7-Bromo-2-Methyl-1H-Indol-3-Ylmethylene)Malononitrile
  参考文献：
  名称：

  Chemical uncouplers for the treatment of obesity

  摘要：

  这项发明涉及一种化学解偶联剂，它具有更宽的安全窗口，使其在治疗肥胖症以及因此引发的相关疾病和状况，如动脉硬化、高血压、糖尿病（尤其是2型糖尿病（非胰岛素依赖型糖尿病））、葡萄糖耐量受损、血脂异常、冠心病、胆结石病、骨关节炎以及子宫内膜、乳房、前列腺和结肠等各种癌症以及过早死亡的风险等方面更具吸引力。此外，还包括其他通过增加线粒体呼吸得到改善的条件、疾病和紊乱。

  公开号：

  US20040138301A1

文献信息

• SAFE CHEMICAL UNCOUPLERS FOR THE TREATMENT OF OBESITY
  申请人：NOVO NORDISK A/S

  公开号：EP1575575A2

  公开（公告）日：2005-09-21
• [EN] SAFE CHEMICAL UNCOUPLERS FOR THE TREATMENT OF OBESITY<br/>[FR] DECOUPLEURS CHIMIQUES SURS POUR LE TRAITEMENT DE L'OBESITE
  申请人：NOVO NORDISK AS

  公开号：WO2004041256A2

  公开（公告）日：2004-05-21

  This invention relates to chemical uncouplers with a broader safety window making the use of them in treating obesity and, consequently, in the treatment of obesity related dis-eases and conditions such as atherosclerosis, hypertension, diabetes, especially type 2 dia-betes (NIDDM (non-insulin dependent diabetes mellitus)), impaired glucose tolerance, dyslip-idemia, coronary heart disease, gallbladder disease, osteoarthritis and various types of can-cer such as endometrial, breast, prostate and colon cancers and the risk for premature death as well as other conditions, such as diseases and disorders, which conditions are improved by an increase in mitochondrial respiration, more attractive.
• Chemical uncouplers for the treatment of obesity
  申请人：——

  公开号：US20040138301A1

  公开（公告）日：2004-07-15

  This invention relates to chemical uncouplers with a broader safety window making the use of them in treating obesity and, consequently, in the treatment of obesity related diseases and conditions such as atherosclerosis, hypertension, diabetes, especially type 2 diabetes (NIDDM (non-insulin dependent diabetes mellitus)), impaired glucose tolerance, dyslipidemia, coronary heart disease, gallbladder disease, osteoarthritis and various types of cancer such as endometrial, breast, prostate and colon cancers and the risk for premature death as well as other conditions, such as diseases and disorders, which conditions are improved by an increase in mitochondrial respiration, more attractive.

  这项发明涉及一种化学解偶联剂，它具有更宽的安全窗口，使其在治疗肥胖症以及因此引发的相关疾病和状况，如动脉硬化、高血压、糖尿病（尤其是2型糖尿病（非胰岛素依赖型糖尿病））、葡萄糖耐量受损、血脂异常、冠心病、胆结石病、骨关节炎以及子宫内膜、乳房、前列腺和结肠等各种癌症以及过早死亡的风险等方面更具吸引力。此外，还包括其他通过增加线粒体呼吸得到改善的条件、疾病和紊乱。